Close Menu

Samuel Waksal, the former CEO of ImClone who was made famous when he went to prison for an insider trading scheme involving home crafts maven Martha Stewart, is out and ready to try again, reports the New York Times' Andrew Pollack. Less than two years after being released from prison, Waksal has started a new biotech company called Kadmon Pharmaceuticals, which he says will have "significant revenues," five Phase 3 products, and a couple of Phase 2 products by next year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new Trump executive order about "free inquiry" on college campuses may threaten $35 billion-worth of federal research funding, reports Ars Technica.

As we enter conference season, Nature News asks why graduate students and postdocs are sometimes forced to choose between paying the rent and paying to attend important meetings.

A new analysis says that a 2018 study claiming to show biparental mtDNA inheritance has several flaws.

In PNAS this week: a genome sequence analysis of Crucihimalaya himalaica, multicellularity and fruiting body development in mushroom-forming fungi, and more.